We hypothesised that the orally-active α 2 -adrenoceptor agonist lofexidine hydrochloride would ameliorate chronic pelvic pain in women. METHODS: A randomized placebo-controlled parallel group trial was undertaken in the University Hospital Gynaecology Clinic. Women with pelvic pain of at least 6 months duration were eligible, and were randomized using a sealed envelope system to receive up to 600 mg lofexidine hydrochloride twice daily over 8 weeks or placebo. Outcome measures were summary and daily diary visual analog scales for pain (VAS) and a 5 point self rating scale. RESULTS: 9/19 women randomized to lofexidine completed the study compared to 14/20 of those randomized to placebo. Intention-to-treat analysis showed that 4/19 in the lofexidine group achieved 50% or greater reduction in VAS compared with 8/20 in the placebo group (OR 2.5, 95% CI 0.6-10.3). Summary and diary VAS were closely correlated. CONCLUSIONS: Within the limits of a small study with power to detect only a substantial effect, we conclude that lofexidine hydrochloride is not effective for the treatment of chronic pelvic pain.
Introduction
Alcorn, 1995) and has previously been evaluated for the alleviation of postmenopausal hot flushes (Jones et al., 1985) . The treatment options for women with chronic pelvic pain remain limited. For women without specific pathology identifiable at laparoscopy, interventions demonstrated to be effective Materials and methods in randomized trials are: ovarian suppression with medroxyThe study was approved by the local Ethics Committee. progesterone acetate; reassurance with the aid of ultrasound scanning; and a multidisciplinary approach to investigation Protocol and treatment (Stones and Mountfield, 1998) . Pelvic venous Premenopausal women with an intact uterus were eligible for entry congestion has been identified in women with pelvic pain into the study if they had had chronic pelvic pain for at least 6 (Metzger, 1998) both radiologically and using ultrasound months; laparoscopy had excluded specific causal pathology such as endometriosis, pelvic inflammatory disease or adhesions; they were scanning (Stones et al., 1990) and the clinical features using effective contraception which was defined as an oral contraceptsuggestive of this condition have been described (Beard ive pill, barrier methods, intrauterine device or sterilization, and did et al., 1988) .
not have symptoms suggestive of irritable bowel syndrome. A power A possible vascular basis for chronic pelvic pain has calculation showed a sample size of 19 in each group to be required prompted the evaluation of vasoactive agents for treatment, by to achieve 90% power to detect as significantly different at the 5% analogy with cerebral migraine. Intravenous dihydroergotamine level the anticipated response rates of 80% and 30% in the lofexidine was shown to ameliorate acute exacerbations of pelvic pain and placebo groups respectively. Treatment was for 8 weeks. The (Reginald et al., 1987) Women were randomized using a sealed envelope system to receive lofexidine hydrochloride or placebo. use of analgesics for non-pelvic pain, predominantly headache. No serious adverse effects were observed. Of the four most common adverse events, drowsiness, dizziness and dry mouth Results were more common in the lofexidine group, and headache and Participant flow and follow-up migraine were more common in the placebo group (Table III) . Nineteen women were randomized to the lofexidine treatment No changes in pulse or blood pressure were observed during arm and 20 to placebo. Baseline characteristics are shown in the study. Table I : the groups were well matched with regard to age, As an assessment of the reliability of the summary pain body mass index (BMI), duration of pain and initial VAS.
Masking
measures, daily diary VAS were compared with the end-ofHowever, the lofexidine group were more parous (median 2) study summary VAS, where women were asked to rate their than the placebo group (P ϭ 0.005). Of those in the lofexidine pain during the second 4 weeks of treatment. The 'usual level group nine completed 8 weeks of treatment compared with 14 of pain' at the end of the study correlated strongly with both in the placebo group. Timing and reasons for discontinuation the mean and summed diary VAS for the previous 4 weeks are shown in Table IIa,b. (both r ϭ 0.88, P Ͻ 0.001, n ϭ 21) and for the 'most severe level of pain' the strongest correlation was with the maximum Analysis diary VAS for the previous 4 weeks (r ϭ 0.85, P Ͻ 0.001, Intention-to-treat analysis of those having 50% or more reducn ϭ 21). tion in VAS, where women who discontinued were considered treatment failures, showed improvement in 4/19 of those Discussion randomized to lofexidine, and 8/20 of those randomized to placebo (OR for improvement 2.5, 95% CI 0.6 to 10.3). The
This pilot study has not demonstrated the therapeutic efficacy of lofexidine in pelvic pain. The study had adequate power to other end points showed similar lack of efficacy. Use of concomitant analgesia did not differ between the groups: detect a substantial treatment effect and the present findings indicate that lofexidine will not have a useful role in this 10/19 of the lofexidine and 8/20 of the placebo group used Lofexidine hydrochloride for chronic pelvic pain indication, but do not exclude a small treatment effect, for pain are appropriate end-point measures for clinical studies in this group of patients. potentially detectable with a larger sample size. These negative findings are unlikely to have arisen because of the higher parity of the lofexidine group, and the groups were otherwise References well matched. We had hypothesised that reduction of sympath- subtype (Hunter et al., 1997) . In an animal model of neuropathic mood (Bryant, 1993) be that α 2 -adrenoceptor agonists would show antinociceptive 191-196. efficacy in human chronic pain syndromes more clearly associated with central sensitisation or neuropathy. Summary VAS
